Although both MAO isoforms metabolize dopamine, MAO-B inhibitors are used in Parkinson’s disease due to safety concerns over early irreversible MAO-A inhibitors, while with aging, the MAO-B isoform increases in the brain, suggesting a more dominant role in dopamine metabolism for MAO-B versus MAO-A. Here, MAOA is linked to Parkinson disease.